Key Developments: Mauna Kea Technologies SA (MKEA.PA)

MKEA.PA on Paris Stock Exchange

4.96EUR
31 Mar 2015
Change (% chg)

-- (--)
Prev Close
€4.96
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
61,271
52-wk High
€13.27
52-wk Low
€4.68

Search Stocks

Latest Key Developments (Source: Significant Developments)

Mauna Kea Technologies' Cellvizio platform is in use by Grenoble University Hospital
11:44am EDT 

Mauna Kea Technologies SA:Says Grenoble University Hospital becomes the first hospital in France to set up a multidisciplinary optical biopsy program with the company's Cellvizio endomicroscopy platform.  Full Article

Mauna Kea Technologies announces positive results with the DETECT study
Wednesday, 25 Mar 2015 12:52pm EDT 

Mauna Kea Technologies SA:Announces positive results with the DETECT study confirming the value of the endomicroscopy for the characterization of pancreatic cysts.  Full Article

Mauna Kea Technologies says Baptist Medical Center in Florida adopts endomicroscopy with Cellvizio
Monday, 23 Mar 2015 01:26pm EDT 

Mauna Kea Technologies SA:Says Baptist Medical Center in Florida adopts endomicroscopy with Cellvizio.  Full Article

Mauna Kea Technologies SA secures funding equity line with Societe Generale
Thursday, 12 Mar 2015 01:24pm EDT 

Mauna Kea Technologies SA:Secures funding equity line with Societe Generale.The use in whole of this line of funding would provide additional funding of 7 million euros.Societe Generale has agreed to purchase 1,390,000 shares (representing 9.9 pct of current capital) over next 10 months, at periods and pace it chooses.  Full Article

Mauna Kea Technologies announces results of Cellvizio tests in esophageal and gastric cancers
Tuesday, 3 Mar 2015 12:03pm EST 

Mauna Kea Technologies SA:Center for Endomicroscopy in China publishes two prospective studies showing advantages of Cellvizio probe-based confocal laser endomicroscopy (pCLE) in the diagnosis of esophageal and gastric cancers.First study presented results of a prospective phase 2 trial showing that the use of pCLE significantly improves specificity of diagnosis in gastric cancer.In the second study pCLE was shown to support the diagnosis of esophageal squamous neoplasia (ESN) with high levels of sensitivity (95 percent) and specificity (91 percent).  Full Article

Mauna Kea Technologies announces positive results from FOCUS pivotal clinical trial on Use of Confocal Laser Endomicroscopy in Biliary Cancer Detection
Tuesday, 27 Jan 2015 11:45am EST 

Mauna Kea Technologies SA:Says publication of the final results of the multi-center international prospective FOCUS clinical trial assessing the use of probe-based confocal laser endomicroscopy (pCLE) in the diagnosis of biliary cancer during endoscopic retrograde cholangio-pancreatography (ERCP).Results were published in the peer-reviewed journal Gastrointestinal Endoscopy, the official journal of the American Society of Gastrointestinal Endoscopy.Results show an improvement in the sensitivity of detection of cholangiocarcinoma, from 56 pct for biopsies to 89 pct for pCLE.  Full Article

Mauna Kea Technologies announces positive results of study on Cellvizio
Wednesday, 14 Jan 2015 12:30pm EST 

Mauna Kea Technologies SA:Announces publication of results of CONTACT 1 prospective multicenter study on Cellvizio.Optical biopsy procedures performed with Cellvizio confirmed nature of benign pancreatic cysts in 100 pct of patients with superficial vascular network.  Full Article

Mauna Kea Technologies announces collaboration with Siemens Healthcare
Monday, 3 Nov 2014 12:00pm EST 

Mauna Kea Technologies SA:Announces collaboration with Siemens Healthcare to evaluate endomicroscopy with Cellvizio in interventional radiology.Doctors will use Cellvizio with Siemens AX and scanner devices in a variety of interventional radiology procedures.Trials will focus on examinations of lungs, liver and kidneys.  Full Article

Mauna Kea Technologies announces results of Cellvizio study with pancreatic cysts
Tuesday, 21 Oct 2014 01:00pm EDT 

Mauna Kea Technologies SA:Clinical study shows Cellvizio allows doctors to confirm benign nature of pancreatic cysts.Results of the study, known as 'Contact 1', were published in the scientific journal Endoscopy.  Full Article

Mauna Kea Technologies says French National Authority for Health approves optical endomicroscopy review
Monday, 13 Oct 2014 01:34am EDT 

Mauna Kea Technologies SA:Says French National Authority for Health approves optical endomicroscopy review during mapping of endo-brachyoesophage on its list of procedures and services.  Full Article

BRIEF-Mauna Kea Technologies' Cellvizio platform is in use by Grenoble University Hospital

* Says Grenoble University Hospital becomes the first hospital in France to set up a multidisciplinary optical biopsy program with the company's Cellvizio endomicroscopy platform Source text: http://bit.ly/1EYY9wI Further company coverage: (Gdynia Newsroom)

Search Stocks